kidney failure News
-
Healionics raises $4.7M equity round to support commercialization of STARgraft vascular graf
Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest. Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access ...
By Healionics
-
Healionics raises $4.5M to fund first-in-human trial of STARgraft vascular graft
Healionics Corporation, a private medical device company, announced today the completion of a $4.5M convertible note financing round. The financing supports the first human study, currently underway, of the company's innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering ...
By Healionics
-
Vascular experts discuss aXess in dialysis patients
Vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of the aXess trial in an interview with Healio Nephrology. For more on Xeltis’ aXess, the first restorative synthetic ...
By XELTIS BV
-
First restorative hemodialysis access graft implanted in patients
Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date. The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. ...
By XELTIS BV
-
Epinex Diagnostics To Present At The BIO CEO & Investor Conference
Epinex Diagnostics, Inc., a private medical company that focuses on point-of-care diagnostic tests, announced today that Asad Zaidi, CEO and James McCarthy, Senior Vice President will present at the 19th annual BIO CEO & Investor Conference in New York, NY on Feb. 13, 2017 at 8:00 a.m. ET in the Conrad Room at the Waldorf Astoria New York. The company has developed three patented innovative ...
-
Xeltis opens new horizons in hemodialysis at VERVE
To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December. In his talk on Saturday 4 December (10am AET), Professor Frans L. Moll, University Medical Center, Utrecht (NL) will explain how the Xeltis synthetic device ...
By XELTIS BV
-
Home Dialysis Patients Face Postcode Lottery of Care, New Report Finds
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
-
US Government to Transform Kidney Care
Osprey Medical (ASX: OSP) today announces its response to the US President signing an Executive Order aimed at transforming kidney care for more than 37 million Americans with some form of kidney disease. The initiative seeks to prevent kidney failure through better diagnosis, treatment and preventative care. Under the Executive Order, the US Federally funded Medicare for people over the age of ...
-
Invizius announces £5.3m Series A
£5.3 million financing to complete First-in-Man safety study Led by Mercia, Downing Ventures, Old College Capital, Scottish Enterprise and Solvay Ventures; welcomes new investors Calculus Capital and Dr Jonathan Milner Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of ...
-
Ellipsys System Offers Significant Advantages for Creating Dialysis Access, Physicians Say
The Ellipsys® Vascular Access System enables patients with kidney failure to start dialysis treatment sooner with fewer procedures, complications and interventions compared to surgery, according to several leading physicians who spoke at the recent meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN). Interventional radiologist Jeffrey Hull, M.D., was awarded ...
-
Healionics Welcomes New Board Director Ryan Takeuchi
Healionics Corporation, a Seattle-based medical device company, has announced the addition of Ryan Takeuchi to its board of directors. Takeuchi brings 20 years of experience in medical devices and private equity, and most recently served as divisional business leader of W.L. Gore’s Medical Products Division. “We appreciate Ryan’s vote of confidence in Healionics and our market ...
By Healionics
-
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for ...
-
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with ...
By Bayer AG
-
Climate study predicts outbreaks of disease spread by rodents
Global warming could be partly to blame for increases in some human and animal viral infections. A new Belgian study investigates the link between climate change and the recent increase in the human disease, nephropathia epidemica (NE), spread by rodents. The authors predict that NE could become a highly endemic disease in Belgium and neighbouring countries. 'Vector-borne' infections are ...
-
Healionics Announces New CEO
Healionics Corporation, a Seattle-based medical device company, today announced the appointment of Mike Connolly as Chief Executive Officer. Connolly brings 25 years of leadership in the medical device industry including extensive experience in both operating and venture investing roles. “We are fortunate to add a leader of Mike’s caliber,” said Andrew Marshall, Director and ...
By Healionics
-
Fresenius Medical Care expands critical care offering with ExThera Medical’s Seraph 100 adsorber
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and covering Belgium, Denmark, France, Germany, ...
-
Healionics Awarded $1.5M SBIR Grant from NIH to Advance Clot-Resistant Synthetic Vascular Graft for Dialysis Patients
Healionics Corporation, a Seattle-based medical device company, was awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to develop new vascular grafts for dialysis use that overcome the major problem of clotting failure. Andrew Marshall, Ph.D., ...
By Healionics
-
Healionics Awarded $1.7M SBIR Grant from NIH to Advance New Vascular Graft Toward First-In-Human Use
Healionics Corporation, a Seattle-based medical device company, has received notice from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of a $1.7M Fast-Track Small Business Innovation Research (SBIR) grant in support of regulatory approval and a clinical study of STARgraftTM, its innovative synthetic vascular graft. Andrew Marshall, Healionics’ Chief Technology ...
By Healionics
-
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients ...
By Bayer AG
-
GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)
GE Healthcare and Osprey Medical Inc. (ASX:OSP) (Osprey) today announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey. Osprey’s DyeVert™ contrast minimization devices, complemented by GE Healthcare's range of iodinated x-ray contrast media, offer healthcare ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you